Vitamin K2 MK-7 in Magnesium Tablets: How Buyers Should Qualify All-Trans Content and Stability

A supplier’s “99% purity” headline cannot tell a formulator whether an MK-7 grade will work in a magnesium tablet. It may describe chemical purity, the proportion of a diluted preparation, or a total MK-7 assay that does not separate geometric isomers. Nor does a raw-material COA establish that the vitamin will survive contact with magnesium oxide through compression and shelf life.

For a repeatable purchase, qualify three things separately: the identity and amount of MK-7, the all-trans/cis profile, and performance in the actual magnesium-containing blend. Keep those as three evidence lines in the specification and approval record. A protected or diluted grade may be the practical choice for a tablet, while a high-assay powder may suit a different process; the decision depends on the finished product, not the largest percentage on a listing.

Why a magnesium tablet changes the purchasing question

MK-7 is a low-dose ingredient. It is commonly supplied in a carrier or protection system so a manufacturer can weigh and distribute it through a larger blend. “Powder” therefore describes a physical format, not a strength. A 10,000 ppm preparation contains 10 mg MK-7 per gram if the ppm statement is weight-for-weight; a 2,000 ppm preparation contains 2 mg/g. A listing that says “99% purity” while also naming a 10,000 ppm preparation has not made those two statements equivalent. Ask the seller to define whether the percentage refers to MK-7 assay, all-trans fraction, a premix component, or another test result.

The mineral also matters. A 2019 study examined three commercial 2,000 ppm MK-7 powders in laboratory blends with calcium citrate, calcium carbonate, arginine, and magnesium oxide. It stored samples at 25°C/60% relative humidity for as long as 12 months and at 40°C/75% relative humidity for up to six months. The results depended on the starting MK-7 material and formulation. Magnesium oxide promoted degradation in the tested systems; the authors also reported that the materials’ purity profiles influenced the outcome. This is a reason to run a formulation-specific study, not a universal prediction that every MK-7 ingredient will fail in every magnesium product.[1]

That distinction is commercially important. A supplier may show a stability result for its own protected grade, but a buyer still needs to know whether the study used the same magnesium salt, carrier, dose, compression process, moisture exposure, packaging, and storage conditions as the product under development. “Stable with minerals” is not a complete test description.

Ask what “all-trans” means on the COA

MK-7 can occur as geometric isomers. Buyers who specify an all-trans grade should make the supplier state the result as a measured attribute, with the analytical method and reporting basis. A total MK-7 assay alone does not demonstrate the all-trans fraction unless the method has been shown to separate and quantify the relevant isomers.

A 2018 analytical study developed and validated a method to identify cis/trans MK-7 isomers in dietary supplements. It examined eight commercial hard-pill products and reported that all-trans content was below the declared amount in most of that small sample; in some products, the measured cis/trans isomers exceeded all-trans MK-7 by as much as 3.7 times.[2] A separate study of oil and non-oil supplements developed methods to separate and measure geometric isomers and other impurities.[3] These are useful signals for procurement controls, but the sample sets are small, dated snapshots of finished products. They do not establish current market-wide failure rates or prove that any particular supplier’s ingredient is nonconforming.

There is also scientific nuance behind the shorthand “cis is inactive.” Research often treats all-trans as the desired form, and laboratory work has found higher carboxylation activity for trans MK-7 under tested conditions. But a 2022 study also reported some activity for cis MK-7 in its in-vitro systems and explicitly left the human significance unresolved.[4] A procurement article should therefore avoid presenting a blanket human-health conclusion. For a product specification, the practical point is narrower: if the formula and label depend on an all-trans MK-7 claim, measure and control that fraction directly.

Ask the supplier to provide:

• The MK-7 assay and whether it is reported as total MK-7 or all-trans MK-7.
• A cis/trans chromatogram or representative method validation showing the peaks are separated.
• The all-trans result as a percentage of total MK-7, plus the assay in the supplied preparation.
• The batch number, test date, laboratory, method reference, and acceptance limits.
• A clear calculation of active MK-7 per gram, including carrier and moisture basis.

The buyer’s own lab or an agreed third-party laboratory should verify the first commercial lot and periodically confirm ongoing performance. Do not accept a certificate that reports “purity 99%” without a definition and method. Analytical selectivity matters: an assay designed for total content may not support an isomer-specific promise. The literature includes methods using chromatographic separation and detectors such as DAD/CAD, with HRMS-QTOF used to support identification; buyers should ask their laboratory to justify the method against the required claim rather than insist on one instrument name without considering validation.[2][3]

Match the ingredient format to the process

High-assay crystalline or concentrated MK-7, diluted premixes, microencapsulated powders, and oil preparations solve different manufacturing problems. Treat the format as part of the raw-material identity.

• Concentrated or high-assay powder: May fit a controlled premix operation with suitable weighing and dispersion. Request assay basis, isomer profile, handling and light controls, and dilution instructions.
• Carrier premix: May simplify direct dosing, uniformity, and practical weighing. Request MK-7 ppm, carrier composition, particle or flow data, and blend-uniformity guidance.
• Protected or microencapsulated powder: May help when separation from reactive minerals is useful. Request the protection-system description, specification basis, and finished-blend data with the intended mineral.
• Oil preparation: May fit softgels, drops, or another oil-based system. Request concentration, solvent or carrier, oxidation and light controls, and package-compatibility data.

This comparison is a screening aid, not a ranking. A high-assay material can reduce the amount of carrier introduced, yet a very small active addition can create weighing and content-uniformity demands. A premix adds mass and carrier, but may be easier to meter and disperse. A coating or capsule wall may reduce direct contact with magnesium, though its performance has to be confirmed in the actual formula. An oil can be appropriate for a lipid system but is not an automatic fit for a dry compressed tablet.

Compare cost only after converting offers to the same basis. If price is quoted per kilogram of a 1% preparation, that is not comparable with a kilogram of a 98% concentrate. Calculate delivered cost per gram of all-trans MK-7 using the stated assay, then include the practical use rate, freight, duties, retest costs, and any carrier or process changes. Do not assume that “99% purity” means 99% active vitamin in a premix.

Keep the dose calculation and batch record on the same basis

A simple conversion catches many purchasing errors. If a preparation is genuinely 10,000 ppm by weight, it contains 10,000 mg MK-7 per kilogram, or 10 mg per gram. To supply a hypothetical 100 micrograms of MK-7 before process losses, the formula would use 10 milligrams of that preparation. The same 100 micrograms from a 2,000 ppm powder would require 50 milligrams. These figures are arithmetic examples only; the product target, overage policy, and regulatory label amount must come from the formulation and quality teams.

The conversion is valid only if ppm is mass-based and the stated assay refers to the same MK-7 quantity used in the formula. If a supplier reports 10,000 ppm total MK-7 but the all-trans fraction is 90% of that total, the all-trans input is different from a product reporting 10,000 ppm all-trans. Have the supplier state both values, then document the value used in the master formula. Do not calculate from the label headline alone.

For each approved lot, retain the supplier COA, incoming identity result, all-trans result, dispensed quantity, batch number, and blend or finished-product test. Reorder controls should define what triggers requalification: a changed fermentation or synthesis source, carrier, encapsulation system, manufacturing site, analytical method, or specification. Set a written notification requirement in the quality agreement. A technically equivalent name does not establish that the new grade behaves equivalently in a low-dose mineral blend.

Sourcing candidate for buyer review

One Alibaba listing for MK-7 is linked below as an RFQ starting point. It is a sourcing route, not a grade approval — the all-trans and stability questions above still decide.

Build a stability protocol around your own tablet

A supplier’s raw-material shelf life describes the unopened ingredient under the supplier’s storage conditions. It does not answer the finished-tablet question. Set a short, decision-oriented study before locking the purchase specification.

First, define the formula variables that matter: the magnesium salt and grade; MK-7 preparation and use level; other alkaline or hygroscopic components; lubricant and disintegrant; tablet moisture; compression settings; and package barrier. If the product uses more than one magnesium source or changes the coating, those changes may alter exposure and should be assessed rather than assumed equivalent.

Prepare at least a control blend without the mineral combination and the proposed production blend. If feasible, include an unprotected and a protected MK-7 option at matched all-trans input. Make pilot tablets using the intended process, not only loose powder blends. Test release samples and retain them in the intended market pack. Include an appropriate accelerated condition for early screening, then use real-time conditions to support the proposed shelf life. Choose conditions and time points with your quality team and destination-market requirements; accelerated results are useful for comparison but are not a substitute for real-time data.

At each point, test all-trans MK-7 with a method that can recover it from the matrix and distinguish it from relevant isomers. Validate extraction from the tablet: a poor extraction can look like degradation. Record total assay separately if it is also part of the control strategy. Add content uniformity or blend-uniformity checks because an average assay can conceal poorly distributed low-dose ingredient. Record appearance, moisture or water activity where relevant, package integrity, and any process observations that could explain changes.

Set acceptance criteria before the study begins. A robust protocol states the target claim, release range, end-of-shelf-life limit, method precision, sample count, time points, packaging, storage conditions, and action if a result fails. If the first pilot loses assay, investigate whether the issue is isomer conversion, oxidation, extraction recovery, blend distribution, or direct interaction with the matrix. These causes lead to different fixes. More overage may hide a weak process temporarily while increasing label and regulatory risk; it should not replace understanding the failure mechanism.

A practical RFQ and supplier qualification sequence

A good RFQ makes suppliers answer the same questions. Ask them to quote the exact grade for the intended use: “MK-7 preparation for a compressed tablet containing magnesium oxide,” then state the target all-trans amount, batch size, market, and desired format. Do not ask only for “vitamin K2 powder,” which can produce offers that differ in active strength and carrier.

Request a current specification, a recent lot-specific COA, an isomer method summary, a sample chromatogram, carrier and protection-system disclosure, allergen and contaminant statements, microbiological limits, residual-solvent data if relevant to the process, storage conditions, retest period, packaging, and change-notification policy. Ask for finished-formula data only with the details needed to interpret it: actual magnesium form and level, MK-7 grade, dosage form, pack, test method, and duration. A graph without those particulars is marketing evidence, not a qualification package.

For an initial technical screen, score each offer against four gates: identity and dose basis; all-trans evidence; suitability of carrier/format for manufacturing; and stability evidence relevant to the target blend. A failure on identity or an undefined assay should stop price comparison. A gap in final-blend data can be handled as a conditional sample evaluation, but record that condition and do not describe the supplier as approved.

The buying decision

For an MK-7 plus magnesium tablet, the best grade is the one whose active basis is unambiguous, whose isomer claim is supported by a suitable method, and whose finished-formula performance has been demonstrated in a representative blend. In practice, request a protected/premix option and a standard option when both are available, compare them at equal all-trans input, and test them through your own compression and packaging process. If the supplier cannot explain what its “purity” number means, cannot separate all-trans from other isomers, or supplies only raw-material stability data, keep the offer at the inquiry stage.

That approach turns a broad ingredient search into a repeatable purchasing standard: same identity, same assay basis, same isomer limit, same test method, and the same finished-product acceptance criteria on every reorder. It also prevents a familiar sourcing mistake—buying a headline percentage that looks precise while leaving the product’s real quality question unanswered.

References

1. Orlando G, et al. “Menaquinone 7 Stability of Formulations and Its Relationship with Purity Profile.” Molecules. 2019;24(5):829. https://pmc.ncbi.nlm.nih.gov/articles/PMC6429189/
2. Szterk A, et al. “Identification of cis/trans isomers of menaquinone-7 in food as exemplified by dietary supplements.” Food Chemistry. 2018;243:403–409. https://pubmed.ncbi.nlm.nih.gov/29146356/
3. Szterk A, et al. “Analysis of Menaquinone-7 Content and Impurities in Oil and Non-Oil Dietary Supplements.” Molecules. 2018;23(5):1056. https://pmc.ncbi.nlm.nih.gov/articles/PMC6102598/
4. Galli F, et al. “Carboxylative efficacy of trans and cis MK7 and comparison with other vitamin K isomers.” Journal of Cellular Biochemistry. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9790681/
5. Orlando G, et al. “A novel method for determination of chemical purity and assay of MK-7; comparison with USP method.” Journal of Pharmaceutical and Biomedical Analysis. 2017. https://pubmed.ncbi.nlm.nih.gov/28024259/